<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Cizzle Biotechnology Holdings Plc — News on 6ix</title>
    <link>https://6ix.com/company/cizzle-biotechnology-holdings-plc</link>
    <description>Latest news and press releases for Cizzle Biotechnology Holdings Plc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 02 Apr 2026 06:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/cizzle-biotechnology-holdings-plc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835e11778dffbe2df126462.webp</url>
      <title>Cizzle Biotechnology Holdings Plc</title>
      <link>https://6ix.com/company/cizzle-biotechnology-holdings-plc</link>
    </image>
    <item>
      <title>£250,000 Funding Facility</title>
      <link>https://6ix.com/company/cizzle-biotechnology-holdings-plc/news/pound250000-funding-facility</link>
      <guid isPermaLink="true">https://6ix.com/company/cizzle-biotechnology-holdings-plc/news/pound250000-funding-facility</guid>
      <pubDate>Thu, 02 Apr 2026 06:00:00 GMT</pubDate>
      <description>Cizzle Biotechnology Holdings plc has secured a new £250,000 funding facility through unsecured convertible loan notes from existing investor Frazer Lang, intended to support the commercial launch of its CIZ1B biomarker test for early lung cancer detection in North America and its rollout in the UK and Europe, as well as further collaborations with Moffitt Cancer Center. This new facility, along with previous convertible loan notes totaling £400,000, can be drawn down by the company between May </description>
    </item>
    <item>
      <title>Progress on Launch of Biomarker Test in USA</title>
      <link>https://6ix.com/company/cizzle-biotechnology-holdings-plc/news/progress-on-launch-of-biomarker-test-in-usa</link>
      <guid isPermaLink="true">https://6ix.com/company/cizzle-biotechnology-holdings-plc/news/progress-on-launch-of-biomarker-test-in-usa</guid>
      <pubDate>Mon, 23 Feb 2026 07:00:00 GMT</pubDate>
      <description>Cizzle Biotechnology Holdings Plc has provided an update on its CIZ1B biomarker test for early lung cancer detection, with its North American partner Cizzle Bio Inc nearing CLIA accreditation in the USA, expected in Q2 2026. The company has received US$590,000 of guaranteed advance payments and has agreed to a revised schedule ensuring the remaining US$1.81m of initial payments are received by the end of 2026. Furthermore, a new agreement includes a minimum of US$3.5m in guaranteed royalty payme</description>
    </item>
    <item>
      <title>Patent Granted in Canada</title>
      <link>https://6ix.com/company/cizzle-biotechnology-holdings-plc/news/patent-granted-in-canada</link>
      <guid isPermaLink="true">https://6ix.com/company/cizzle-biotechnology-holdings-plc/news/patent-granted-in-canada</guid>
      <pubDate>Wed, 04 Feb 2026 07:00:00 GMT</pubDate>
      <description>Cizzle Biotechnology Holdings PLC has announced the granting of patents in Canada for methods measuring the CIZ1B lung cancer biomarker, strengthening its commercialisation efforts in North America and the Caribbean through its subsidiary Cizzle Bio Inc. This follows existing patent coverage in the USA, with further US patent expected, and existing protection from the European Patent Office. The company is actively seeking partnerships in the UK and Europe, including with the NHS, aligning with </description>
    </item>
    <item>
      <title>£250,000 Convertible Loan Note Issue</title>
      <link>https://6ix.com/company/cizzle-biotechnology-holdings-plc/news/pound250000-convertible-loan-note-issue</link>
      <guid isPermaLink="true">https://6ix.com/company/cizzle-biotechnology-holdings-plc/news/pound250000-convertible-loan-note-issue</guid>
      <pubDate>Wed, 05 Nov 2025 07:01:00 GMT</pubDate>
      <description>£250,000 Convertible Loan Note Issue.</description>
    </item>
    <item>
      <title>LOI with leading UK Clinical Diagnostic Group</title>
      <link>https://6ix.com/company/cizzle-biotechnology-holdings-plc/news/loi-with-leading-uk-clinical-diagnostic-group</link>
      <guid isPermaLink="true">https://6ix.com/company/cizzle-biotechnology-holdings-plc/news/loi-with-leading-uk-clinical-diagnostic-group</guid>
      <pubDate>Wed, 05 Nov 2025 07:00:00 GMT</pubDate>
      <description>LOI with leading UK Clinical Diagnostic Group.</description>
    </item>
    <item>
      <title>Change of Registered Office</title>
      <link>https://6ix.com/company/cizzle-biotechnology-holdings-plc/news/change-of-registered-office-75</link>
      <guid isPermaLink="true">https://6ix.com/company/cizzle-biotechnology-holdings-plc/news/change-of-registered-office-75</guid>
      <pubDate>Mon, 27 Oct 2025 11:32:00 GMT</pubDate>
      <description>Cizzle Biotechnology Holdings PLC, a UK-based diagnostics developer of early cancer tests, announced a change of registered office effective immediately. The company&apos;s new registered office and UK head office is located at c/o Ampa Holdings LLP, Level 19, The Shard, 32 London Bridge Street, London, SE1 9SG; the previous address was 6th Floor, 60 Gracechurch Street, London, EC3V 0HR.

                Disclaimer*</description>
    </item>
    <item>
      <title>Interim Results</title>
      <link>https://6ix.com/company/cizzle-biotechnology-holdings-plc/news/interim-results-193</link>
      <guid isPermaLink="true">https://6ix.com/company/cizzle-biotechnology-holdings-plc/news/interim-results-193</guid>
      <pubDate>Tue, 30 Sep 2025 06:00:00 GMT</pubDate>
      <description>Cizzle Biotechnology Holdings PLC announced its interim results for the six months ended 30 June 2025. The company received US$400,000 of the agreed US$2.4 million up-front fees and advanced royalty payments, with a further US$125,000 received in July, totaling US$525,000. A convertible loan note raised £150,000 to support growth and partnerships for its CIZ1B early cancer test. The company reported a loss for the period of £368,000, a significant decrease from the £1,411,000 loss in the first h</description>
    </item>
    <item>
      <title>Update on Clinical Laboratory Partnerships in USA</title>
      <link>https://6ix.com/company/cizzle-biotechnology-holdings-plc/news/update-on-clinical-laboratory-partnerships-in-usa</link>
      <guid isPermaLink="true">https://6ix.com/company/cizzle-biotechnology-holdings-plc/news/update-on-clinical-laboratory-partnerships-in-usa</guid>
      <pubDate>Mon, 29 Sep 2025 06:00:00 GMT</pubDate>
      <description>Cizzle Biotechnology announced progress in the commercial rollout of its CIZ1B biomarker test in North America through its partner Cizzle Bio Inc (BIO). BIO is completing validation with Omni Health Diagnostics, expanding testing capability across multiple states. BIO is making regular payments as part of the revised advance royalty payment schedule of US$2.4 million, to be paid in full by the end of 2026. These payments are advance payments from royalties of 10% on sales revenue in North Americ</description>
    </item>
    <item>
      <title>Commercial Progress in USA</title>
      <link>https://6ix.com/company/cizzle-biotechnology-holdings-plc/news/commercial-progress-in-usa</link>
      <guid isPermaLink="true">https://6ix.com/company/cizzle-biotechnology-holdings-plc/news/commercial-progress-in-usa</guid>
      <pubDate>Mon, 18 Aug 2025 06:00:00 GMT</pubDate>
      <description>Cizzle Biotechnology Holdings plc announced that its North American licensing partner, Cizzle Bio Inc (BIO), has agreed with a multi-site clinical diagnostics laboratory group to launch the company&apos;s CIZ1B biomarker test in the USA.  This follows progress with a pathfinder laboratory.  BIO has made an early payment of US$125,000 in advance royalties, bringing total receipts to US$525,000 against guaranteed advance payments of US$2.4 million.  A revised payment schedule means the remaining US$1,8</description>
    </item>
    <item>
      <title>Result of AGM</title>
      <link>https://6ix.com/company/cizzle-biotechnology-holdings-plc/news/result-of-agm-344</link>
      <guid isPermaLink="true">https://6ix.com/company/cizzle-biotechnology-holdings-plc/news/result-of-agm-344</guid>
      <pubDate>Mon, 30 Jun 2025 12:45:00 GMT</pubDate>
      <description>Result of AGM.</description>
    </item>
    <item>
      <title>Notice of AGM</title>
      <link>https://6ix.com/company/cizzle-biotechnology-holdings-plc/news/notice-of-agm-167</link>
      <guid isPermaLink="true">https://6ix.com/company/cizzle-biotechnology-holdings-plc/news/notice-of-agm-167</guid>
      <pubDate>Fri, 06 Jun 2025 10:00:00 GMT</pubDate>
      <description>Notice of AGM.</description>
    </item>
    <item>
      <title>Holding(s) in Company</title>
      <link>https://6ix.com/company/cizzle-biotechnology-holdings-plc/news/holdings-in-company-394</link>
      <guid isPermaLink="true">https://6ix.com/company/cizzle-biotechnology-holdings-plc/news/holdings-in-company-394</guid>
      <pubDate>Wed, 28 May 2025 06:00:00 GMT</pubDate>
      <description>Holding(s) in Company.</description>
    </item>
    <item>
      <title>£150,000 Convertible Loan Note Issue</title>
      <link>https://6ix.com/company/cizzle-biotechnology-holdings-plc/news/pound150000-convertible-loan-note-issue</link>
      <guid isPermaLink="true">https://6ix.com/company/cizzle-biotechnology-holdings-plc/news/pound150000-convertible-loan-note-issue</guid>
      <pubDate>Tue, 20 May 2025 06:00:00 GMT</pubDate>
      <description>£150,000 Convertible Loan Note Issue.</description>
    </item>
    <item>
      <title>Final results for the year ended 31 December 2024</title>
      <link>https://6ix.com/company/cizzle-biotechnology-holdings-plc/news/final-results-for-the-year-ended-31-december-2024-9</link>
      <guid isPermaLink="true">https://6ix.com/company/cizzle-biotechnology-holdings-plc/news/final-results-for-the-year-ended-31-december-2024-9</guid>
      <pubDate>Wed, 30 Apr 2025 10:18:00 GMT</pubDate>
      <description>Final results for the year ended 31 December 2024.</description>
    </item>
    <item>
      <title>Contract in Caribbean and Update on CIZ1B</title>
      <link>https://6ix.com/company/cizzle-biotechnology-holdings-plc/news/contract-in-caribbean-and-update-on-ciz1b</link>
      <guid isPermaLink="true">https://6ix.com/company/cizzle-biotechnology-holdings-plc/news/contract-in-caribbean-and-update-on-ciz1b</guid>
      <pubDate>Mon, 28 Apr 2025 06:00:00 GMT</pubDate>
      <description>Contract in Caribbean and Update on CIZ1B.</description>
    </item>
    <item>
      <title>Launch of New Website</title>
      <link>https://6ix.com/company/cizzle-biotechnology-holdings-plc/news/launch-of-new-website-5</link>
      <guid isPermaLink="true">https://6ix.com/company/cizzle-biotechnology-holdings-plc/news/launch-of-new-website-5</guid>
      <pubDate>Mon, 14 Apr 2025 09:00:00 GMT</pubDate>
      <description>Launch of New Website.</description>
    </item>
    <item>
      <title>Appointment of Non-Executive Director</title>
      <link>https://6ix.com/company/cizzle-biotechnology-holdings-plc/news/appointment-of-non-executive-director-82</link>
      <guid isPermaLink="true">https://6ix.com/company/cizzle-biotechnology-holdings-plc/news/appointment-of-non-executive-director-82</guid>
      <pubDate>Tue, 25 Mar 2025 07:00:00 GMT</pubDate>
      <description>Appointment of Non-Executive Director.</description>
    </item>
    <item>
      <title>Update on Launch of CIZ1B Biomarker Assay</title>
      <link>https://6ix.com/company/cizzle-biotechnology-holdings-plc/news/update-on-launch-of-ciz1b-biomarker-assay</link>
      <guid isPermaLink="true">https://6ix.com/company/cizzle-biotechnology-holdings-plc/news/update-on-launch-of-ciz1b-biomarker-assay</guid>
      <pubDate>Mon, 24 Mar 2025 07:00:00 GMT</pubDate>
      <description>Update on Launch of CIZ1B Biomarker Assay.</description>
    </item>
    <item>
      <title>Appointment of Professor Dawn Coverley as CSO</title>
      <link>https://6ix.com/company/cizzle-biotechnology-holdings-plc/news/appointment-of-professor-dawn-coverley-as-cso</link>
      <guid isPermaLink="true">https://6ix.com/company/cizzle-biotechnology-holdings-plc/news/appointment-of-professor-dawn-coverley-as-cso</guid>
      <pubDate>Thu, 02 Jan 2025 07:00:00 GMT</pubDate>
      <description>Appointment of Professor Dawn Coverley as CSO.</description>
    </item>
    <item>
      <title>Update on Strategic Partnership in North America</title>
      <link>https://6ix.com/company/cizzle-biotechnology-holdings-plc/news/update-on-strategic-partnership-in-north-america</link>
      <guid isPermaLink="true">https://6ix.com/company/cizzle-biotechnology-holdings-plc/news/update-on-strategic-partnership-in-north-america</guid>
      <pubDate>Mon, 16 Dec 2024 07:00:00 GMT</pubDate>
      <description>Update on Strategic Partnership in North America.</description>
    </item>
  </channel>
</rss>